Flash Finance

Epigral LimitedEPIGRALCorporate

Chemicals Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹995.80
MCap ₹4,296 Cr · P/E 15.8
Epigral Limited — Stock analysis & AI research Epigral Limited — Multibagger AI analysis Epigral Limited — Seasonality — best & worst months Epigral Limited — Technical indicators & charts Epigral Limited — Technical setup — score, trend, support & resistance Epigral Limited — Live exchange announcements
📋 Stocks Cheaper Than Their Industry📋 High Promoter Holding Stocks 📈 Lowest Technical Score📈 Multi-Timeframe Bearish Stocks 🏭 Chemicals sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹705 Cr
Sales · Jun 2026
+16.3% YoY
₹179 Cr
Operating Profit · Jun 2026
+9.7% YoY
25.4%
OPM % · Jun 2026
-5.6% YoY
₹100 Cr
Net Profit · Jun 2026
-37.9% YoY
₹23.12
EPS · Jun 2026
-37.9% YoY

📝 Epigral Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Epigral Limited reported revenue of ₹705 crore for the quarter ended June 2026 (Q1 FY27), up 16.3% from ₹607 crore in the same quarter last year, and down 4.2% sequentially over the March 2026 quarter.

Net profit fell 37.9% year-on-year to ₹100 crore, from ₹161 crore. Earnings per share (EPS) came in at ₹23.12.

Operating profit stood at ₹179 crore — an operating margin (OPM) of 25.4%, compared with 26.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Epigral Limited posted revenue of ₹2,527 crore, a decline of 0.9% over FY25, with a net profit of ₹332 crore (down 7.2% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,626 crore with a net profit of ₹271 crore.

Valuation snapshot

At the current price of ₹995.80, EPIGRAL has a market capitalisation of ₹4,296 crore and a trailing P/E of about 15.8.

Within the Chemicals industry, it is the 21st-largest of the 79 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 68.83%, foreign institutional investors (FIIs) 0.99%, domestic institutional investors (DIIs) 4.90%, the government 0.02%, public shareholders 25.26% of Epigral Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹4,296 Cr
Current Price ?
₹995.8
P/E ?
15.85below ind
Industry P/E ?
24.60
P/B ?
1.93
P/S ?
1.64
P/FCF ?
85.92
Enterprise Value ?
₹4,868 Cr
EV/EBITDA ?
8.37
PEG ?
N/A
Earnings Yield ?
8.5%
Dividend Yield ?
0.51%
Profitability & Returns
Sales (TTM) ?
₹2,626 Cr
OPM ?
22.2%
Profit after tax (TTM) ?
₹271 Cr
EPS (TTM) ?
₹62.83
ROCE ?
15.0%
ROE ?
12.2%
ROA ?
7.7%
Growth
Sales — latest qtr ?
₹705 Cr
PAT — latest qtr ?
₹100 Cr
YoY qtr sales growth ?
16.3%
YoY qtr profit growth ?
-37.9%
Sales growth (3y) ?
5%
Sales growth (5y) ?
25%
Profit growth (3y) ?
-2%
Profit growth (5y) ?
27%
Financial Health
Debt ?
₹572 Cr
Debt to Equity ?
0.26
Interest Coverage ?
5.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
68.83%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-5.3%
Return 6 months ?
-17.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 562455478472525651626645628607587597736705 +16.3% -4.2%
Operating Profit 15595108123155176178183173163132103168179 +9.7% +6.9%
Other Income 521222643826-15 -43.5% +917.5%
Interest 19182120141427-012232211167 -69.1% -54.3%
Depreciation 3031323130333233344242434243 +3.3% +2.9%
Profit Before Tax 1104756741131311251541311077055110134 +25.0% +22.1%
Net Profit 7732384977868110487161513981100 -37.9% +23.2%
EPS 18.477.589.1411.8118.6020.6719.5724.2520.1437.2511.879.0818.7623.12 -37.9% +23.2%
OPM % 27.5% 20.9% 22.6% 26.0% 29.6% 27.1% 28.5% 28.3% 27.6% 26.9% 22.5% 17.2% 22.8% 25.4% -5.6% +11.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,550 Cr ₹2,527 Cr ₹2,626 Cr -0.9%
Operating Profit ₹711 Cr ₹566 Cr ₹582 Cr -20.3%
OPM % 27.87% 22.40% 22.16% -19.6%
NPM % 14.03% 13.14% 10.32% -6.3%
Other Income ₹15 Cr ₹15 Cr ₹11 Cr -2.1%
Depreciation ₹133 Cr ₹168 Cr ₹170 Cr +27.0%
Interest ₹53 Cr ₹72 Cr ₹56 Cr +35.1%
EBIT ₹578 Cr ₹398 Cr ₹412 Cr -31.2%
PBT ₹541 Cr ₹341 Cr ₹368 Cr -37.0%
Tax ₹183 Cr ₹9 Cr ₹96 Cr -95.2%
Net Profit ₹358 Cr ₹332 Cr ₹271 Cr -7.2%
EPS ₹84.63 ₹76.96 ₹62.83 -9.1%
Material Cost ₹1,322 Cr ₹1,491 Cr ₹1,603 Cr +12.7%
Employee Cost ₹114 Cr ₹130 Cr ₹136 Cr +13.3%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 42424343 +0.0%
Reserves 1,0281,2131,8612,178 +17.0%
Borrowings 879964593572 -3.5%
Other Liabilities 484576655712 +8.7%
Total Liabilities 2,4322,7943,1523,505 +11.2%
Fixed Assets 1,8041,7672,2382,117 -5.4%
CWIP 15848364451 +604.7%
Investments 21219823 -76.5%
Other Assets 450524752915 +21.7%
Total Assets 2,4322,7943,1523,505 +11.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 626398441436 -1.1%
Cash from Investing Activity -437-401-262-355 -35.5%
Cash from Financing Activity -200-8-164-94 +42.7%
Net Cash Flow -11-1115-14 -193.3%
Free Cash Flow 210-125450 -80.3%
CFO/OP 106%93%78%90% +15.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 28343360 +81.8%
Inventory Days 699010589 -15.2%
Days Payable 36635066 +32.0%
Cash Conversion Cycle 61618883 -5.7%
Working Capital Days -41-542616 -38.5%
ROCE % 32%17%25%15% -40.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 68.83%68.83%68.83%68.83%68.83%68.83% +0.0%
FIIs 3.06%2.71%2.36%1.54%1.03%0.99% -3.9%
DIIs 4.78%4.93%5.13%4.90%5.56%4.90% -11.9%
Government 0.02%0.02%0.02%0.02%0.02%0.02% +0.0%
Public 23.30%23.52%23.67%24.71%24.55%25.26% +2.9%
No. of Shareholders 79,95178,60577,56277,58376,30576,384 +0.1%

⚖️ Peer comparison

Industry: Chemicals · top 25 of 79 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 NAVINFLUOR Navin Fluorine ₹8,545.00 43,843 55.4 3,634 790 33.9% 21.7% 41.1% 130.1% 44.1% 107.7%
2 DEEPAKNTR Deepak Nitrite ₹1,596.00 21,768 27.8 8,575 784 15.5% 9.1% -4.8% -22.5% 36.4% 207.4%
3 DEEPAKFERT Deepak Fertilisers ₹1,323.00 16,718 17.0 12,103 985 16.7% 8.1% 12.0% -21.8% 22.5% 101.0%
4 TATACHEM Tata Chemicals ₹615.00 15,668 — 15,120 -1,971 11.3% -13.0% -2.0% -543.2% 14.4% -81.0%
5 PCBL PCBL Chemical ₹331.50 13,043 43.3 6,596 298 13.4% 4.5% -12.5% -46.0% 17.0% 64.8%
6 JUBLINGREA Jubilant Ingrevia ₹647.25 10,208 33.3 4,651 308 13.4% 6.6% 5.1% 10.3% 25.3% 40.9%
7 ALKYLAMINE Alkyl Amines ₹1,818.60 9,301 41.3 1,658 225 20.6% 13.5% -2.3% -3.8% 30.1% 93.1%
8 CLEAN Clean Science ₹820.00 8,715 37.4 982 232 35.7% 23.6% -2.5% -13.7% 21.9% -4.7%
9 GNFC Gujarat Narmada ₹539.75 7,931 7.6 8,410 1,037 14.8% 12.3% -1.5% 35.3% 39.8% 275.9%
10 GALAXYSURF Galaxy Surfactants ₹2,156.30 7,887 21.6 5,752 353 10.4% 6.1% 24.3% -50.0% 39.4% 108.7%
11 NEOGEN Neogen Chemicals ₹2,403.50 7,221 180.9 926 36 16.6% 3.8% 10.9% -17.6% 34.0% 66.8%
12 BALAMINES Balaji Amines ₹2,215.00 7,177 35.3 1,523 211 21.4% 13.9% 2.0% 6.5% 27.2% 113.9%
13 FCL Fineotex Chemical ₹53.07 6,180 41.6 1,012 148 16.7% 14.6% 44.8% 14.5% 174.8% 92.6%
14 ACI Archean Chemical ₹470.90 5,814 61.0 1,123 95 20.3% 8.5% 7.8% -37.0% 8.9% -24.4%
15 GULFOILLUB Gulf Oil ₹1,057.20 5,235 13.9 4,367 371 12.6% 8.5% 11.7% -3.4% 30.6% 27.0%
16 FOSECOIND Foseco India ₹6,846.50 5,186 64.7 618 77 17.5% 12.5% 12.2% -1.9% 9.2% 8.9%
17 GUJALKALI Gujarat Alkalies ₹696.50 5,115 77.0 4,497 66 11.2% 1.5% 7.0% 96.3% 12.6% 499.0%
18 LXCHEM Laxmi Organic ₹178.50 4,961 40.2 3,117 123 8.2% 4.0% -4.7% -43.4% 44.1% 194.8%
19 VISHNU Vishnu Chemicals ₹724.90 4,880 32.6 1,694 150 15.5% 8.8% 11.1% 12.2% 24.9% 23.0%
20 YASHO Yasho Industries ₹4,028.70 4,857 84.9 939 57 19.5% 6.1% 24.0% 771.1% 54.9% 801.3%
21 EPIGRAL Epigral ₹1,084.00 4,677 17.3 2,626 271 22.2% 10.3% -0.9% -7.2% 16.3% -37.9%
22 TATVA Tatva Chintan ₹1,867.60 4,369 85.0 556 51 19.3% 9.2% 32.6% 702.6% 42.8% 128.3%
23 GHCL GHCL ₹418.85 3,839 7.4 3,043 525 23.0% 17.3% -3.7% -23.5% -2.7% 31.8%
24 PREMEXPLN Premier Explosives ₹685.10 3,685 110.0 349 34 6.8% 9.6% -7.0% 60.5% -27.8% -80.2%
25 GRAUWEIL Grauer & Weil ₹76.61 3,474 21.2 1,190 165 16.2% 13.9% 5.8% 11.0% 4.4% 92.3%
❓ Frequently asked questions
What was Epigral Limited's revenue in Q1 FY27?
Epigral Limited reported revenue of ₹705 crore for the quarter ended June 2026 (Q1 FY27), up 16.3% from ₹607 crore in the same quarter last year, and down 4.2% sequentially over the March 2026 quarter.
What was Epigral Limited's net profit in Q1 FY27?
Net profit fell 37.9% year-on-year to ₹100 crore, from ₹161 crore. Earnings per share (EPS) came in at ₹23.12.
What is EPIGRAL's market capitalisation and P/E ratio?
At the current price of ₹995.80, EPIGRAL has a market capitalisation of ₹4,296 crore and a trailing P/E of about 15.8.
Who owns Epigral Limited? (shareholding pattern)
As of Sep 2026, promoters held 68.83%, foreign institutional investors (FIIs) 0.99%, domestic institutional investors (DIIs) 4.90%, the government 0.02%, public shareholders 25.26% of Epigral Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI